期刊
EXPERT OPINION ON DRUG SAFETY
卷 21, 期 9, 页码 1171-1181出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14740338.2022.2122437
关键词
Dalbavancin; adverse effects; ABSSSI; real-world studies
Dalbavancin is a safe and well-tolerated drug for the treatment of acute bacterial skin and skin-structure infections. Common adverse effects include gastrointestinal symptoms, infusion reaction, and hypersensitivity. Further research is needed for the off-label use of dalbavancin.
Introduction Dalbavancin is a second-generation lipoglycopeptide approved since 2014 to treat acute bacterial skin and skin-structure infections (ABSSSI). Dalbavancin is characterized by Gram-positive activity and novel pharmacokinetic properties allowing prolonged terminal half-life andonce weekly dosing . A good safety profile was reported in clinical trials . Areas covered Dalbavancin safety and tolerability from trials and post-marketing studies were reviewed. While most reports included predominantly ABSSSI, two clinical trials and recent observational studies have explored the use of dalbavancin for off-label indications, mainly including bloodstream and osteoarticular infections. Expert opinion The occurrence of drug-related adverse effects (AE) was similar between dalbavancin and comparators in clinical trials enrolling patients with ABSSSI. Most common AE included gastrointestinal symptoms, infusion reaction, and hypersensitivity. Low rates of drug discontinuation and serious AE were reported across studies. In the past 5 years, several observational studies have reported safety data on the use of dalbavancin, confirming its favorable safety profile. Nevertheless, data from dalbavancin off-label use, often derived from prolonged (>2 weeks) treatments with variable dosing regimens, were mainly retrospective and lacked comparators. Further research is required to allow a reliable analysis of short- and long-term dalbavancin-related AE in non-ABSSSI.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据